Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 14/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.60 |
| ▸ | CETP | P11597 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814976 | 0.94 | ALDH1A1 (0.68) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL11732563 | 0.94 | ALDH1A1 (0.68) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL11734795 | 0.93 | ALDH1A1 (0.70) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL11729230 | 0.90 | ALDH1A1 (0.66) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL14855849 | 0.89 | ALDH1A1 (0.58) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL15528295 | 0.89 | RXFP1 (0.75) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL16404476 | 0.86 | ALDH1A1 (0.60) | ALDH1A1RXFP1HPGDKDM4ENPSR1 | |
| SCHEMBL28170369 | 0.86 | ALDH1A1 (0.60) | ALDH1A1RXFP1HPGDKDM4ENPSR1 | |
| SCHEMBL15528518 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNARXFP1HPGDKDM4E | |
| SCHEMBL16669873 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNARXFP1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | claimed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | claimed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | claimed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | claimed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 2846/4885LMNA 3109/4885RXFP1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.